Resistance to immunotherapy treatments such as trastuzumab in gastric cancer patients has been seen by the loss of Her-2 expression post treatment (12) and the upregulation of PDL1 leading to escape mechanism and progression (13, 14). The gene discussed is ERBB2; the disease is gastric cancer.